118 related articles for article (PubMed ID: 8247943)
21. A partial role of serotonin in normalization of the bleeding time by DDAVP in uraemic rats.
Pietraszek M; Azzadin A; Buczko W; Malyszko J; Mysliwiec M
Thromb Haemost; 1992 Nov; 68(5):625. PubMed ID: 1455414
[No Abstract] [Full Text] [Related]
22. Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity.
Horstman LL; Valle-Riestra BJ; Jy W; Wang F; Mao W; Ahn YS
Thromb Res; 1995 Jul; 79(2):163-74. PubMed ID: 7676403
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo effects of desmopressin on platelet function.
Balduini CL; Noris P; Belletti S; Spedini P; Gamba G
Haematologica; 1999 Oct; 84(10):891-6. PubMed ID: 10509036
[TBL] [Abstract][Full Text] [Related]
24. Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6.
Newby DE; Stewart A; Witherow FN; Grieve S; Dawson P; Fox KA; Webb DJ; Ludlam CA
Thromb Haemost; 2000 Aug; 84(2):195-203. PubMed ID: 10959689
[TBL] [Abstract][Full Text] [Related]
25. Effect of deamino-8-D-arginine desmopressin in uremic bleeding.
Hong SY; Yang DH
Korean J Intern Med; 1996 Jun; 11(2):145-50. PubMed ID: 8854651
[TBL] [Abstract][Full Text] [Related]
26. Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms.
Lethagen S; Rugarn P; Aberg M; Nilsson IM
Acta Chir Scand; 1990 Sep; 156(9):597-602. PubMed ID: 1702252
[TBL] [Abstract][Full Text] [Related]
27. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding.
Svensson PJ; Bergqvist PB; Juul KV; Berntorp E
Blood Rev; 2014 May; 28(3):95-102. PubMed ID: 24703870
[TBL] [Abstract][Full Text] [Related]
28. Desmopressin (dDAVP): a powerful general hemostatic agent?
Drouet L; Scrobohaci ML; Boudaoud S; Vilain G
Nouv Rev Fr Hematol (1978); 1989; 31(2):163-5. PubMed ID: 2528120
[No Abstract] [Full Text] [Related]
29. Patients with prolonged bleeding time of undefined etiology, and their response to desmopressin.
Kim HC; Salva K; Fallot PL; Karp GI; Eisele J; Matts L; Heller I; Saidi P
Thromb Haemost; 1988 Apr; 59(2):221-4. PubMed ID: 3388295
[TBL] [Abstract][Full Text] [Related]
30. Desmopressin--a haemostatic drug: state-of-the-art review.
Lethagen S
Eur J Anaesthesiol Suppl; 1997 Mar; 14():1-9. PubMed ID: 9088828
[TBL] [Abstract][Full Text] [Related]
31. 1-Deamino-8-d-arginine vasopressin (DDAVP): a potential new treatment for the bleeding diathesis of acute renal failure.
Watson AJ; Keogh JA
Pharmatherapeutica; 1984; 3(9):618-22. PubMed ID: 6728864
[TBL] [Abstract][Full Text] [Related]
32. 1-Deamino-8 D-arginine vasopressin decreases the production of 13-hydroxyoctadecadienoic acid by endothelial cells.
Setty BN; Dampier CD; Stuart MJ
Thromb Res; 1992 Sep; 67(5):545-58. PubMed ID: 1448788
[TBL] [Abstract][Full Text] [Related]
33. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass.
de Prost D; Barbier-Boehm G; Hazebroucq J; Ibrahim H; Bielsky MC; Hvass U; Lacombe C; Français JL; Desmonts JM
Thromb Haemost; 1992 Aug; 68(2):106-10. PubMed ID: 1412152
[TBL] [Abstract][Full Text] [Related]
34. [Shortening of acetylsalicylic acid-prolonged bleeding time by means of desmopressin].
Beck KH; Bleckmann U; Mohr P; Kretschmer V; Huss B
Beitr Infusionsther Transfusionsmed; 1994; 32():437-9. PubMed ID: 9480140
[TBL] [Abstract][Full Text] [Related]
35. Effects of DDAVP administrated subcutaneously in dogs with aspirin-induced platelet dysfunction and hemostatic impairment due to chronic liver diseases.
Sakai M; Watari T; Miura T; Maruyama H; Koie H; Yamaya Y; Takeuchi A; Hasegawa A
J Vet Med Sci; 2003 Jan; 65(1):83-6. PubMed ID: 12576709
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
37. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
38. Force monitoring of clot retraction during DDAVP therapy for the qualitative platelet disorder of uraemia: report of a case.
Carr ME; Zekert SL
Blood Coagul Fibrinolysis; 1991 Apr; 2(2):303-8. PubMed ID: 1893061
[TBL] [Abstract][Full Text] [Related]
39. Involvement of Na+/H+ exchanger in desmopressin-induced platelet procoagulant response.
Tomasiak MM; Stelmach H; Bodzenta-Łukaszyk A; Tomasiak M
Acta Biochim Pol; 2004; 51(3):773-88. PubMed ID: 15448738
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the fibrinolytic response to desmopressin acetate (DDAVP) infusion versus venous occlusion in patients with coronary artery disease.
Duprez D; Baele G; De Buyzere M; Vandenbroecke P; Clement DL
Eur Heart J; 1991 Jul; 12(7):800-2. PubMed ID: 1909628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
